Day: July 25, 2022

´╗┐Although a phase III trial in patients with platinum-sensitive repeated OC didn’t show the efficacy of farletuzumab [15], our results claim that GC may be a promising focus on tumor type for farletuzumab therapy. stabilization for 25 and Retinyl glucoside 20?a few months was seen in a single individual with crystal clear cell OC (100?mg/m2) […]